<DOC>
	<DOCNO>NCT00005884</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use eflornithine may effective way prevent recurrence development skin cancer . PURPOSE : Randomized phase III trial determine effectiveness eflornithine prevent skin cancer patient previously receive treatment early stage skin cancer .</brief_summary>
	<brief_title>Eflornithine Prevent Skin Cancer Patients With Previously Treated Early Stage Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare rate new skin cancer patient previously treat stage 0 , I , II basal squamous cell skin cancer treat eflornithine ( DFMO ) v placebo . II . Determine whether inhibition TPA-induced ornithine decarboxylase activity serve intermediary marker response DFMO patient . III . Determine whether inhibition skin polyamine level serve intermediary marker response DFMO patient . IV . Assess long term toxic effect treatment patient . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients receive oral placebo daily first 4 week . Patients comply take 80-100 % placebo randomized one two treatment arm . Arm I : Patients receive oral eflornithine ( DFMO ) daily . Arm II : Patients receive oral placebo daily . Treatment continue 3-5 year absence unacceptable toxicity . Patients develop skin cancer study undergo surgical excision continue treatment arm originally randomize . Patients follow every 6 month year 5 . PROJECTED ACCRUAL : A total 334 patient ( 167 per arm ) accrue study 2 year .</detailed_description>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously treat stage 0 , I , II basal squamous cell skin cancer PATIENT CHARACTERISTICS : Age : 21 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 11.0 g/dL Hepatic : Bilirubin great 2 mg/dL SGOT le 3 time normal Renal : Creatinine le 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant clinical hearing loss use hearing aid No family history early retinal blindness ornithine diaminotransferase deficiency PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplant No concurrent tamoxifen cancer treatment prophylaxis Chemotherapy : Greater 4 week since prior chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy : Greater 4 week since prior hormonal therapy cancer No concurrent prednisone No concurrent hormonal therapy cancer treatment prophylaxis Radiotherapy : Greater 4 week since prior radiotherapy Surgery : Greater 4 week since prior major surgery No prior solid organ transplant Other : At least 4 week since prior topical medication ( e.g. , tretinoin , isotretinoin , psoralen ultraviolet light therapy , fluorouracil ) skin cancer No concurrent antiseizure medication</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
</DOC>